retatrutide parkinson's disease trial π¨Breaking: Retatrutide's first Phase 3 T2D data just dropped. βΈ A1C: β2.0% at 40 weeks βΈ Weight: β36.6 lbs (β16.8%) at 12 mg βΈ No weight loss plateau β curve still descending ESC 2024: Retatrutide improves lipid
Description
ROSE-010, a GLP-1 analog, was tested in a randomized, placebo-controlled clinical trial for treating acute pain in IBS patients [56]
Clinical trials show non-diabetic patients lose 10 to 22 percent of baseline body weight over 68 weeks, depending on dose and adherence
GLP-1 users such as Ozempic experience rapid results
Ziyad Al-Aly, who led the study, told the outlet that consistent results across alcohol, opioids and stimulants really elevates the notion that these medications are really acting on the root causes of all of these addictions
Quality varies dramatically
